RU2003118436A - ANKARA MODIFIED VERSION OF ANKARA - Google Patents

ANKARA MODIFIED VERSION OF ANKARA

Info

Publication number
RU2003118436A
RU2003118436A RU2003118436/13A RU2003118436A RU2003118436A RU 2003118436 A RU2003118436 A RU 2003118436A RU 2003118436/13 A RU2003118436/13 A RU 2003118436/13A RU 2003118436 A RU2003118436 A RU 2003118436A RU 2003118436 A RU2003118436 A RU 2003118436A
Authority
RU
Russia
Prior art keywords
virus
paragraphs
inoculation
vaccine
genome
Prior art date
Application number
RU2003118436/13A
Other languages
Russian (ru)
Other versions
RU2290438C2 (en
Inventor
Пол Чаплин
Пол Хаули
Кристине МАЙЗИНГЕР
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of RU2003118436A publication Critical patent/RU2003118436A/en
Application granted granted Critical
Publication of RU2290438C2 publication Critical patent/RU2290438C2/en

Links

Claims (27)

1. Вирус коровьей оспы, имеющий, по меньшей мере, одно из следующих свойств:1. The vaccinia virus, having at least one of the following properties: (i) способность к репродукции путем репликации в фибробластах эмбрионов цыплят (CEF) и в линии клеток почек детенышей хомячка BHK, но отсутствие способности к репродукции путем репликации в клеточной линии кератиноцитов человека HaCat,(i) the ability to reproduce by replication in fibroblasts of chicken embryos (CEF) and in the cell line of the kidney cells of young BHK hamster, but the lack of ability to reproduce by replication in the cell line of human keratinocytes HaCat, (ii) отсутствие способности к репликации in vivo,(ii) lack of in vivo replication ability, (iii) индукция более сильного иммунитета по сравнению с известным штаммом MVA 575 в модели летального заражения и/или(iii) the induction of stronger immunity compared to the known strain MVA 575 in the model of lethal infection and / or (iv) индукция, по меньшей мере, по существу того же самого уровня иммунитета при режимах первичной иммунизации вирусом коровьей оспы/повторной иммунизации вирусом коровьей оспы по сравнению с режимами первичной иммунизации ДНК/повторной иммунизации вирусом коровьей оспы.(iv) the induction of at least substantially the same level of immunity in the primary vaccination with vaccinia virus / reimmunization with vaccinia virus compared with the primary immunization with DNA / reimmunization with vaccinia virus. 2. Вирус по п. 1, где вирус не способен к репродукции путем репликации в любой из следующих клеточных линий человека: линии клеток почки эмбриона человека 293, клеточной линии остеосаркомы кости человека 143B и клеточной линии аденокарциномы шейки матки человека HeLa.2. The virus of claim 1, wherein the virus is not capable of reproduction by replication to any of the following human cell lines: human embryonic kidney cell line 293, human bone osteosarcoma cell line 143B, and human cervical adenocarcinoma cell line HeLa. 3. Вирус по п. 1 или 2, положенный на хранение в Европейскую коллекцию клеточных культур (ECACC) Salisbury (UK) под номером V00083008, и его производные.3. The virus according to claim 1 or 2, deposited in the European collection of cell cultures (ECACC) Salisbury (UK) under the number V00083008, and its derivatives. 4. Вирус по любому из пп. 1-3, включающий, по меньшей мере, одну последовательность гетерологичной нуклеиновой кислоты.4. The virus according to any one of paragraphs. 1-3, comprising at least one heterologous nucleic acid sequence. 5. Вирус по п. 4, где указанная последовательность гетерологичной нуклеиновой кислоты выбрана из последовательности, кодирующей, по меньшей мере, один антиген, антигенный эпитоп и/или терапевтическое соединение.5. The virus of claim 4, wherein said heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope and / or therapeutic compound. 6. Геном или его функциональные части, происходящие от вируса по любому из пп. 1-5.6. The genome or its functional parts originating from the virus according to any one of paragraphs. 1-5. 7. Фармацевтическая композиция, включающая вирус по любому из пп. 1-5, и/или геном, и/или его функциональную часть по п. 6, и фармацевтически приемлемый носитель, разбавитель и/или добавку.7. A pharmaceutical composition comprising a virus according to any one of paragraphs. 1-5, and / or the genome, and / or its functional part according to claim 6, and a pharmaceutically acceptable carrier, diluent and / or additive. 8. Вакцина, включающая вирус, по любому из пп. 1-5, и/или геном, и/или его функциональную часть по п. 6.8. The vaccine comprising the virus, according to any one of paragraphs. 1-5, and / or the genome, and / or its functional part according to claim 6. 9. Вирус по любому из пп. 1-5, геном и/или его функциональная часть по п. 6, композиция по п. 7, или вакцина по п. 8, в качестве лекарства для влияния на иммунный ответ, предпочтительно для его индукции, у живого животного, включая человека.9. The virus according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, the composition according to claim 7, or the vaccine according to claim 8, as a medicine for influencing the immune response, preferably for its induction, in a living animal, including humans. 10. Вирус по любому из пп. 1-5, фармацевтическая композиция по п. 7, вакцина по п. 8, или вирус по п. 9, где вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции (“примирующая инокуляция”) и при второй инокуляции (“бустерная инокуляция”).10. The virus according to any one of paragraphs. 1-5, the pharmaceutical composition according to claim 7, the vaccine according to claim 8, or the virus according to claim 9, wherein the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation (“priming inoculation”) and during the second inoculation (“ booster inoculation ”). 11. Применение вируса по любому из пп. 1-5, и/или генома по п.6, для получения лекарства или вакцины.11. The use of the virus according to any one of paragraphs. 1-5, and / or genome according to claim 6, to obtain a medicine or vaccine. 12. Способ введения гомологичной и/или гетерологичной последовательности нуклеиновой кислоты в клетки-мишени, включающий инфицирование клеток-мишеней вирусом по п. 4 или 5, или трансфекцию клетки-мишени геномом по п. 6.12. A method for introducing a homologous and / or heterologous nucleic acid sequence into target cells, comprising infecting the target cells with a virus according to claim 4 or 5, or transfecting the target cell with a genome according to claim 6. 13. Способ получения пептида, белка и/или вируса, включающий13. A method of producing a peptide, protein and / or virus, comprising a) инфицирование клетки-хозяина вирусом по п. 1 или 5,a) infection of the host cell with a virus according to claim 1 or 5, b) культивирование инфицированной клетки-хозяина в подходящих условиях иb) culturing the infected host cell under suitable conditions and c) выделение и/или повышение концентрации пептида, и/или белка, и/или вирусов, продуцируемых указанной клеткой-хозяином.c) isolating and / or increasing the concentration of the peptide and / or protein and / or viruses produced by said host cell. 14. Способ влияния на иммунный ответ, предпочтительно его индукцию, в организме живого животного, включая человека, включающий введение вируса, по любому из пп. 1-5, генома и/или его функциональной части по п.6, композиции по п. 7, или вакцины по п. 8, животному или человеку, подвергаемому лечению.14. The method of influencing the immune response, preferably its induction, in the body of a living animal, including humans, including the introduction of the virus, according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, the composition according to claim 7, or the vaccine according to claim 8, to an animal or person being treated. 15. Способ по п. 14, включающий введение, по меньшей мере, 102 TCID50 (дозы инфицирования в тканевой культуре) вируса.15. The method according to p. 14, comprising the introduction of at least 10 2 TCID 50 (dose of infection in tissue culture) of the virus. 16. Способ по п. 14 или 15, в котором вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции (“примирующая инокуляция”) и при второй инокуляции (“бустерная инокуляция”).16. The method according to p. 14 or 15, in which the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation (“priming inoculation”) and during the second inoculation (“booster inoculation”). 17. Способ по любому из пп. 14-16, где животное имеет нарушенный иммунитет.17. The method according to any one of paragraphs. 14-16, where the animal has impaired immunity. 18. Способ по любому из пп. 14-17, где животное имеет уже существующий иммунитет по отношению к вирусам оспы.18. The method according to any one of paragraphs. 14-17, where the animal has a pre-existing immunity against smallpox viruses. 19. Способ по любому из пп. 14-18, где животное подвергается противовирусной терапии.19. The method according to any one of paragraphs. 14-18, where the animal undergoes antiviral therapy. 20. Способ по п. 19, где противовирусная терапия представляет собой терапию против ретровирусов.20. The method according to p. 19, where the antiviral therapy is a therapy against retroviruses. 21. Применение вируса по любому из пп. 1-5, генома и/или его функциональной части по п. 6, в качестве адъюванта.21. The use of the virus according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, as an adjuvant. 22. Способ увеличения специфического иммунного ответа против антигена и/или антигенного эпитопа, включенного в вакцину, включающий введение в качестве адъюванта вируса по любому из пп. 1-5, или генома по п. 6, в организм живого животного, включая человека, подвергаемого лечению вакциной.22. A method of increasing a specific immune response against an antigen and / or antigenic epitope included in a vaccine, comprising administering as a adjuvant the virus according to any one of claims. 1-5, or the genome of claim 6, into the body of a living animal, including the person being treated with the vaccine. 23. Вирус, по любому из пп. 1-5, или геном по п. 6, в качестве адъюванта.23. The virus, according to any one of paragraphs. 1-5, or the genome according to claim 6, as an adjuvant. 24. Клетка, предпочтительно клетка человека, содержащая вирус по любому из пп. 1-5, или геном, или его функциональную часть по п. 6.24. A cell, preferably a human cell, containing the virus according to any one of claims. 1-5, or the genome, or its functional part according to claim 6. 25. Способ получения вируса коровьей оспы, по любому из пп. 1-3, включающий следующие стадии:25. The method of obtaining the vaccinia virus, according to any one of paragraphs. 1-3, including the following stages: - введение обычного доступного штамма вируса коровьей оспы, предпочтительно MVA 575 в клетки, отличные от клеток человека, в которых вирус способен к репродукции путем репликации, где клетки, отличные от клеток человека, предпочтительно выбраны из клеток CEF и клеточной линии BHK,- introducing the usual available strain of vaccinia virus, preferably MVA 575, into cells other than human cells, in which the virus is capable of reproduction by replication, where cells other than human cells are preferably selected from CEF cells and the BHK cell line, - выделение/увеличение концентрации вирусных частиц из данных клеток и- isolation / increase in the concentration of viral particles from these cells and - анализ того, будет ли полученный вирус иметь, по меньшей мере, одно из биологических свойств, как указано в п. 1,- analysis of whether the resulting virus will have at least one of the biological properties, as described in paragraph 1, где указанные выше стадии могут необязательно повторяться до тех пор, пока не будет получен вирус с желаемыми репликативными характеристиками.where the above steps may optionally be repeated until a virus with the desired replicative characteristics is obtained. 26. Набор для примирующей/бустерной иммунизации, включающий вирус по любому из пп. 1-5, композицию по п. 7, вакцину по п.8, или вирус по п. 9, для первой инокуляции (“примирующая инокуляция”) в первом флаконе/контейнере и для второй инокуляции (“бустерная инокуляция”) во втором флаконе/контейнере.26. A kit for priming / booster immunization, comprising the virus according to any one of paragraphs. 1-5, the composition of claim 7, the vaccine of claim 8, or the virus of claim 9, for the first inoculation (“reconciliation inoculation”) in the first vial / container and for the second inoculation (“booster inoculation”) in the second vial / container. 27. Применение вируса по любому из пп. 1-5, композиции по п. 7, вакцины по п. 8 или вируса по п. 9 для получения вакцины, где вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции и при второй инокуляции.27. The use of the virus according to any one of paragraphs. 1-5, the composition according to p. 7, the vaccine according to p. 8 or the virus according to p. 9 to obtain a vaccine, where the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation and the second inoculation.
RU2003118436/13A 2000-11-23 2001-11-22 Modified variant of ankara vaccina virus RU2290438C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001764 2000-11-23
DKPA200001764 2000-11-23

Publications (2)

Publication Number Publication Date
RU2003118436A true RU2003118436A (en) 2004-12-27
RU2290438C2 RU2290438C2 (en) 2006-12-27

Family

ID=8159864

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003118436/13A RU2290438C2 (en) 2000-11-23 2001-11-22 Modified variant of ankara vaccina virus

Country Status (30)

Country Link
US (11) US7189536B2 (en)
EP (4) EP2204452A1 (en)
JP (1) JP4421188B2 (en)
KR (3) KR20090057335A (en)
CN (2) CN101676389A (en)
AT (1) ATE314483T2 (en)
AU (2) AU3163902A (en)
BE (1) BE2013C065I2 (en)
BR (1) BRPI0115533B8 (en)
CA (1) CA2421151C (en)
CY (2) CY1105594T1 (en)
CZ (1) CZ295808B6 (en)
DE (2) DE60116371T3 (en)
DK (1) DK1335987T4 (en)
EE (1) EE05680B1 (en)
ES (1) ES2256323T5 (en)
FR (1) FR13C0070I2 (en)
HK (1) HK1059453A1 (en)
HU (2) HU230198B1 (en)
IL (2) IL154712A0 (en)
LU (1) LU92311I2 (en)
MX (1) MXPA03002513A (en)
NO (1) NO337867B1 (en)
NZ (1) NZ524661A (en)
PL (1) PL212047B1 (en)
PT (1) PT1335987E (en)
RU (1) RU2290438C2 (en)
SI (1) SI1335987T2 (en)
UA (1) UA76731C2 (en)
WO (1) WO2002042480A2 (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
CA2466413C (en) 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
EP1839672A3 (en) * 2002-04-19 2007-11-21 Bavarian Nordic A/S Modified vaccinia virus Ankara for the vaccination of neonates
EA009525B1 (en) * 2002-05-16 2008-02-28 Бавариан Нордик А/С Recombinant modified vaccinia virus ankara comprising the cowpox ati promoter and methods of use virus and promoter
EA007811B1 (en) 2002-05-16 2007-02-27 Бавариан Нордик А/С Intergenic regions as insertion sites in the genome of modified vaccine virus ankara (mva)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101044538B1 (en) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DK1536015T3 (en) * 2003-11-24 2008-02-18 Bavarian Nordic As Promoters for expression in modified vaccinia virus Ankara
ES2357772T3 (en) * 2004-06-14 2011-04-29 Ishihara Sangyo Kaisha, Ltd. LIOFILIZED COMPOSITION OF INACTIVATED VIRAL WRAPPING WITH MEMBRANE FUSION ACTIVITY.
CN1295339C (en) * 2005-01-11 2007-01-17 武汉大学 Attenuated vaccinia virus Tiantan strain vector and its preparation and application
BRPI0608310A2 (en) 2005-02-23 2009-12-08 Bavarian Nordic As use of a modified poxvirus for rapid induction of immunity against a poxvirus or other infectious agents
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
KR100717279B1 (en) * 2005-08-08 2007-05-15 삼성전자주식회사 Mask rom device and method of formimg the same
US7913477B2 (en) * 2006-01-27 2011-03-29 William Anthony Harper Insert registration in packets
EP1826264A1 (en) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primate model for orthopox virus infections
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
BRPI0713711A2 (en) 2006-06-20 2012-10-30 Transgene Sa recombinant viral vaccine, vaccination kit, and method for using at least one compound
EP2064351A1 (en) * 2006-09-08 2009-06-03 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
CA2665068C (en) 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
JP2010526546A (en) 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ Purification of vaccinia virus and recombinant vaccinia virus vaccines
EP2207564B1 (en) * 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
KR100970449B1 (en) * 2007-12-21 2010-07-16 (주)이지아이 Safety rubber plate for children playground and construction method its
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
PL2382474T3 (en) 2009-01-20 2015-08-31 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20110138354A (en) 2009-03-24 2011-12-27 트랜스진 에스.에이. Biomarker for monitoring patients
SG175060A1 (en) 2009-04-17 2011-11-28 Transgene Sa Biomarker for monitoring patients
HUE028240T2 (en) 2009-07-10 2016-12-28 Transgene Sa Biomarker for selecting patients and related methods
EA201270108A1 (en) 2009-10-08 2012-08-30 Бавариан Нордик А/С FORMATION OF POLYSPECIFIC T-CELL RESPONSE AGAINST HIV IN HUMAN
EP2501405A4 (en) * 2009-11-20 2013-12-04 Inviragen Inc Compositions, methods and uses for poxvirus elements in vaccine constructs
AU2011209175B2 (en) 2010-01-28 2016-02-04 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of MVA
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US10087423B2 (en) 2010-07-20 2018-10-02 Bavarian Nordic A/S Method for harvesting expression products
WO2012018856A2 (en) * 2010-08-02 2012-02-09 Virxsys Corporation Hiv vaccine therapy with concomitant antiviral monotherapy
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
PL2691530T3 (en) 2011-06-10 2019-02-28 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PL2739293T3 (en) * 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
KR20150058152A (en) 2012-07-10 2015-05-28 트랜스진 에스아이 Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EA201891945A3 (en) 2012-08-01 2019-05-31 Бавариан Нордик А/С VACCINE OF THE RECOMBINANT MODIFIED ANPARA OSPOVACZINA VIRUS (MVA) RESPIRATORY-SYNCYTIAL VIRUS (RSV)
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
KR20200087880A (en) 2012-10-28 2020-07-21 버베리안 노딕 에이/에스 Pr13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015061416A2 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
EA039037B1 (en) 2013-11-28 2021-11-24 Бавариан Нордик А/С Recombinant poxvirus for enhancing innate immune response in a vertebrate and use thereof
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
ES2851451T3 (en) 2014-05-13 2021-09-07 Bavarian Nordic As Combination therapy to treat cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
SG11201701745TA (en) 2014-09-03 2017-04-27 Bavarian Nordic As Methods and compositions for enhancing immune responses
KR101963985B1 (en) 2014-09-03 2019-07-31 버베리안 노딕 에이/에스 Methods and compositions for inducing protective immunity against filovirus infection
RS61902B1 (en) 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
KR101623498B1 (en) 2014-10-16 2016-05-24 대한민국 Kvacattenuated vaccinia virus kvac strain
KR101645642B1 (en) 2014-10-16 2016-08-11 대한민국 Kvac recombinant vaccinia virus derived from kvac strain
CA2965562C (en) 2014-11-04 2023-11-21 Janssen Vaccines & Prevention B.V. Therapeutic hpv16 vaccines
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
RU2020132040A (en) 2015-05-20 2020-10-12 Те Брод Инститьют Инк. GENERAL NEOANTIGENS
TW202241500A (en) 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
CN107709554A (en) * 2015-06-15 2018-02-16 巴法里安诺迪克有限公司 Restructuring is through modifying vaccinia virus ankara (MVA) foot and mouth disease virus (FMDV) vaccine
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
FR3042121A1 (en) 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
CN106591361A (en) * 2015-10-20 2017-04-26 钱文斌 Recombinant pox oncolytic virus, and construction method and application thereof
AU2016369326B2 (en) 2015-12-15 2019-02-21 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
PL3407910T3 (en) 2016-01-29 2022-08-16 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
MX2018010231A (en) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors.
MX2018010204A (en) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy.
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
US10273268B2 (en) 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
HUE052008T2 (en) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
RU2756534C2 (en) 2016-09-28 2021-10-01 Бавариан Нордик А/С Compositions and methods for increasing the stability of transgenes in poxviruses
AU2017347725B2 (en) 2016-10-17 2024-01-04 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
CA3042703A1 (en) 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
CA3045650A1 (en) 2016-12-05 2018-06-14 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CN111107872A (en) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 Vaccinia virus mutants useful for cancer immunotherapy
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
MA49397A (en) 2017-06-15 2020-04-22 Bavarian Nordic As POXVIRUS VECTORS CODING FOR HIV ANTIGENS, AND METHODS FOR USING THEM
BR112020000867A2 (en) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. hiv envelope protein mutations stabilizing the trimer
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
AU2018320417A1 (en) 2017-08-24 2020-02-27 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
BR112020012273A2 (en) 2017-12-19 2020-11-24 Janssen Sciences Ireland Unlimited Company methods and compositions to induce an immune response against the hepatitis b virus (hbv)
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
EA202091517A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
AU2018392884B2 (en) 2017-12-20 2021-11-11 Glaxosmithkline Biologicals Sa Epstein-Barr Virus antigen constructs
JP2021511318A (en) 2018-01-19 2021-05-06 ヤンセン ファーマシューティカルズ，インコーポレーテッド Induction and enhancement of immune response using recombinant replicon system
US20220001001A1 (en) * 2018-07-13 2022-01-06 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
JP2022512595A (en) 2018-10-05 2022-02-07 バヴァリアン・ノルディック・アクティーゼルスカブ Combination therapy to treat cancer by intravenous administration of recombinant MVA and immune checkpoint antagonists or immune checkpoint agonists
CA3119736A1 (en) 2018-11-14 2020-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
TW202110476A (en) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
EP3983012A1 (en) 2019-06-11 2022-04-20 GlaxoSmithKline Biologicals S.A. Mucosal vaccine formulations
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CA3159666A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva)
JP2023503857A (en) 2019-11-20 2023-02-01 バヴァリアン・ノルディック・アクティーゼルスカブ Recombinant MVA virus for intratumoral and/or intravenous administration to treat cancer
CA3165251A1 (en) 2020-01-21 2021-07-29 Jeffrey Schlom Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
WO2021150713A2 (en) 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs)
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2021250219A1 (en) 2020-06-10 2021-12-16 Bavarian Nordic A/S A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
KR20230050328A (en) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 RNA replicon vaccine against HBV
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
AU2022338199A1 (en) 2021-09-03 2024-03-14 Bavarian Nordic A/S Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003346A1 (en) 2022-06-30 2024-01-04 Bavarian Nordic A/S Mammalian cell line for the production of modified vaccinia virus ankara (mva)
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
US3914408A (en) 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (en) 1977-04-01 1978-10-05 Mayr Anton PREPARATION FOR TREATING HERPES ZOSTER AND OTHER HERPES INFECTIONS AND METHOD FOR THE PRODUCTION THEREOF
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
AU613583B2 (en) 1986-08-22 1991-08-08 Transgene S.A. Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
FR2603040B1 (en) 1986-08-22 1990-01-26 Transgene Sa PROTEIN, DNA SEQUENCE, POXVIRUSES, CELLS AND THEIR CULTURE PROCESS, AS WELL AS THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USEFUL IN THE PREVENTION OF SCHISTOSOMOSIS
DE3743298A1 (en) 1987-12-19 1989-06-29 Wilkinson Sword Gmbh SHAVING APPARATUS AND METHOD FOR PRODUCING A LAYER OF LOW FRICTION RESISTANCE ON A SHAVING APPARATUS
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
EP0550638A4 (en) 1990-09-25 1993-12-08 Smithkline Beecham Corporation Medium for culture of mammalian cells
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5490794A (en) * 1993-11-05 1996-02-13 Sumitomo Wiring Systems, Ltd. Branch joint box
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (en) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
WO1996003144A1 (en) * 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5566011A (en) * 1994-12-08 1996-10-15 Luncent Technologies Inc. Antiflector black matrix having successively a chromium oxide layer, a molybdenum layer and a second chromium oxide layer
UA68327C2 (en) † 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
JP2000517290A (en) 1996-02-21 2000-12-26 リスジーウィックス，ジュリアナ Methods and compositions for protective and therapeutic gene immunization
WO1998004680A1 (en) 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
AU4556597A (en) † 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) 1996-10-25 1998-04-30 The Wistar Institute Of Anatomy & Biology Method of vaccinating infants against infections
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
US20030138454A1 (en) 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
DE19729279A1 (en) † 1997-07-09 1999-01-14 Peter Hildebrandt Urological implant, in particular vascular wall support for the urinal tract
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EP1137769B1 (en) 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
GB2370572B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Use of a professional antigen presenting cell
KR20010084935A (en) 1998-11-18 2001-09-07 찰스 굿맨 Polypeptide
US6173813B1 (en) 1998-12-23 2001-01-16 Otis Elevator Company Electronic control for an elevator braking system
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
CA2401974C (en) * 2000-03-02 2013-07-02 Emory University Dna expression vectors and methods of use
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
KR100341030B1 (en) 2000-03-16 2002-06-20 유태욱 method for replaying caption data and audio data and a display device using the same
KR20030036194A (en) 2000-05-24 2003-05-09 메리알 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant poxvirus vaccine
AU2001270631B2 (en) 2000-07-11 2005-07-07 Bayer Aktiengesellschaft Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
CA2466413C (en) * 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
NZ533586A (en) 2001-12-20 2005-02-25 Bavarian Nordic As Method for the recovery and purification of poxviruses from infected cells using high pressure homogenisation
AU2003219057A1 (en) 2002-03-15 2003-09-29 Baxter Healthcare S.A. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
EP1839672A3 (en) * 2002-04-19 2007-11-21 Bavarian Nordic A/S Modified vaccinia virus Ankara for the vaccination of neonates
EA007811B1 (en) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Intergenic regions as insertion sites in the genome of modified vaccine virus ankara (mva)
EA009525B1 (en) * 2002-05-16 2008-02-28 Бавариан Нордик А/С Recombinant modified vaccinia virus ankara comprising the cowpox ati promoter and methods of use virus and promoter
KR101044538B1 (en) * 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
PT1567653E (en) * 2002-11-25 2007-10-01 Bavarian Nordic As Recombinant poxvirus comprising at least two cowpox ati promoters
US6976752B2 (en) * 2003-10-28 2005-12-20 Lexmark International, Inc. Ink jet printer with resistance compensation circuit
DK1536015T3 (en) * 2003-11-24 2008-02-18 Bavarian Nordic As Promoters for expression in modified vaccinia virus Ankara
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
WO2006044716A2 (en) * 2004-10-15 2006-04-27 Washington University In St.Louis CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
CA2665068C (en) * 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2207564B1 (en) * 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer

Similar Documents

Publication Publication Date Title
RU2003118436A (en) ANKARA MODIFIED VERSION OF ANKARA
RU2280075C2 (en) Alternated strain of modified vaccinia virus ankara (mva)
JP2926270B2 (en) Pharmaceutical composition for prevention and treatment of papillomavirus-induced tumors
JPH025860A (en) Recombinant vaccinia virus mva
ES2424847T3 (en) Foot and mouth disease virus genes expressing recombinant avipox
UA75411C2 (en) Recombinant virus of mva
JP5166505B2 (en) Recombinant MVA and production method thereof
JP2002186494A (en) Recombinant vaccinia virus
EP1420822A2 (en) Modified vaccinia virus ankara for the vaccination of neonates
CN1842602A (en) Modified vaccinia virus ankara (MVA) mutant and use thereof
CN101142319B (en) Vaccines based on the use of mv
WO2022071513A1 (en) IMPROVED DNA VACCINE FOR SARS-CoV-2
DE10144664A1 (en) New vaccinia virus MVA-E3L knock-out mutant, useful for generating recombinant MVA viruses or host cells, comprises an inactivated MVA ORF 050L gene in its viral genome
CN109536529A (en) A kind of efficient vaccinia virus recombinant carrier and its method for building up
CA2223419A1 (en) Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses
JP2000502900A (en) Recombinant virus pseudoparticles and their vaccines and antitumor uses
JPH10512151A (en) Immunogenic compositions containing recombinant attenuated poxvirus expressing HTLV antigen
ES2258628T3 (en) LEPORIPOX-BASED VECTOR VACCINES.
US20110064769A1 (en) Vv promoter-driven overexpression of recombinant antigens
RU2588388C1 (en) Recombinant strain l-ivp 1421abjcn pox virus virulence genes with broken a56r, b8r, j2r, c3l, n1l for producing live culture of attenuated smallpox vaccine and other orthopoxviruses, pathogenic for humans
RIAZANKIN et al. Recombinant Strain of Vaccinia Virus Capable of Producing a Chimeric Protein TBI-Hbs Ag
WO1998015635A2 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine